Naphazoline
From Wikipedia, the free encyclopedia
 |
|
|
Naphazoline
|
|
| Systematic (IUPAC) name | |
| 2-(naphthalen-1-ylmethyl)-4,5-dihydro-1H-imidazole | |
| Identifiers | |
| CAS number | |
| ATC code | R01 |
| PubChem | |
| Chemical data | |
| Formula | C14H14N2 |
| Mol. mass | 210.274 |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | Topical |
Naphazoline (in the hydrochloride form) is the common name for 2-(1-naphthylmethyl)-2-imidazoline hydrochloride. It is a sympathomimetic agent with marked alpha adrenergic activity. It is a vasoconstrictor with a rapid action in reducing swelling when applied to mucous membrane. It acts on alpha-receptors in the arterioles of the conjunctiva to produce constriction, resulting in decreased congestion. It is an active ingredient in Naphcon-A and Clearine eye drops.
It has the molecular formula C14H14N2.HCl and a molecular weight of 246.73 g/mol.
[edit] Warnings and contraindications
A few warnings and contraindications that apply to all naphazoline-containing substances intended for medicinal use are:
- Hypersensitivity to naphazoline
- Patients taking MAO inhibitors can experience a severe hypertensive crisis if given a sympathomimetic drug such as naphazoline HCl
- Use in infants and children can result in central nervous system depression, leading to coma and marked reduction in body temperature
- Should be used with caution in patients with severe cardiovascular disease including cardiac arrythmia and in patients with diabetes, especially those with a tendency toward diabetic ketoacidosis
- Drug interactions can occur with anaesthetics that sensitize the myocardium to sympathomimetics (e.g cyclopropane or halothane cautiously
- Exercise caution when applying prior to use of phenylephrine.
|
|||||||||||||||||
